These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8632719)

  • 21. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delineating biochemical and functional properties of sigma receptors: emerging concepts.
    Su TP
    Crit Rev Neurobiol; 1993; 7(3-4):187-203. PubMed ID: 8106175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroleptics with differential affinities at dopamine D2 receptors and sigma receptors affect differently the N-methyl-D-aspartate-induced increase in intracellular calcium concentration: involvement of protein kinase.
    Hayashi T; Su TP; Kagaya A; Nishida A; Shimizu M; Yamawaki S
    Synapse; 1999 Jan; 31(1):20-8. PubMed ID: 10025680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential antidepressant activity of sigma ligands.
    Skuza G
    Pol J Pharmacol; 2003; 55(6):923-34. PubMed ID: 14730086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Atypical antipsychotic profiles of sigma receptor ligands].
    Okuyama S
    Nihon Yakurigaku Zasshi; 1999 Jul; 114(1):13-23. PubMed ID: 10562961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats.
    Skuza G; Rogóz Z
    J Physiol Pharmacol; 2006 Jun; 57(2):217-29. PubMed ID: 16845227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo characterization of phencyclidine/sigma agonist-mediated inhibition of nociception.
    DeLander GE; Wahl JJ
    Eur J Pharmacol; 1989 Jan; 159(2):149-56. PubMed ID: 2468511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic treatment of rats with the specific sigma ligand D-pentazocine fails to modulate dopamine D2 and sigma binding in brain.
    Weissman AD; De Souza EB
    Eur J Pharmacol; 1991 Mar; 195(1):163-5. PubMed ID: 1648492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo functional interaction between phencyclidine binding sites and sigma receptors to produce head-weaving behavior in rats.
    Kitaichi K; Noda Y; Hasegawa T; Furukawa H; Nabeshima T
    Eur J Pharmacol; 1996 Dec; 318(2-3):205-11. PubMed ID: 9016907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine.
    Takahata R; Moghaddam B
    Neuropsychopharmacology; 2003 Jun; 28(6):1117-24. PubMed ID: 12700703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands.
    Monnet FP; Debonnel G; de Montigny C
    J Pharmacol Exp Ther; 1992 Apr; 261(1):123-30. PubMed ID: 1532832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of sigma receptor ligands on psychiatric disorders].
    Kamei H; Noda Y; Nabeshima T; Yamada K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Oct; 23(5):187-96. PubMed ID: 14653224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals.
    Hashimoto K; Ishiwata K
    Curr Pharm Des; 2006; 12(30):3857-76. PubMed ID: 17073684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of brain NMDA receptors: common mechanism of sigma/PCP receptors and their exogenous and endogenous ligands.
    Sircar R; Samaan H; Nichtenhauser R; Snell LD; Johnson KM; Rivier J; Vale W; Zukin RS; Zukin SR
    NIDA Res Monogr; 1986; 75():157-60. PubMed ID: 2828962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine.
    Peeters M; Romieu P; Maurice T; Su TP; Maloteaux JM; Hermans E
    Eur J Neurosci; 2004 Apr; 19(8):2212-20. PubMed ID: 15090047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of sigma (σ) receptor ligands from a behavioral perspective.
    Skuza G
    Curr Pharm Des; 2012; 18(7):863-74. PubMed ID: 22288408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of [3H]Dopamine release from rat nucleus accumbens by neuropeptide Y may involve a sigma1-like receptor.
    Ault DT; Radeff JM; Werling LL
    J Pharmacol Exp Ther; 1998 Feb; 284(2):553-60. PubMed ID: 9454797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes.
    Heresco-Levy U; Javitt DC
    Eur Neuropsychopharmacol; 1998 May; 8(2):141-52. PubMed ID: 9619693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition.
    Whittemore ER; Ilyin VI; Woodward RM
    J Pharmacol Exp Ther; 1997 Jul; 282(1):326-38. PubMed ID: 9223571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.